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Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in
the airways, parenchyma and vessels, which can cause a structural remodeling with
increased fibrosis that narrows and fixes the airway lumen. Transforming growth factor-b1
(TGF-b1), a multifunctional growth factor, was reported to be increased in the airways of
COPD patients. In this study, we hypothesized that polymorphisms in the TGF-b1 gene
would be associated with an accelerated rate of decline of forced expiratory volume in 1 s
(FEV1). Three polymorphisms, 509 (C-T), +869 (T-C) and +915 (G-C), located in TGF-
b1 gene were genotyped. We determined the prevalence of these polymorphisms in 590
continuing smokers who had the fastest (n ¼ 283) and slowest (n ¼ 307) rate of decline of
lung function from the NHLBI Lung Health Study. There was no association between these
TGF-b1 polymorphisms and the rate of decline of FEV1, but in a post-hoc analysis the
genotype distribution at +869 was significantly different between high and low responders
to methacholine (P ¼ 0:04). These data suggest that the T–C polymorphism at position
+869 in the TGF-b1 gene contributes to airway hyperresponsiveness, but not to rapid
decline of lung function.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is characterized
by chronic inflammation in the airways, parenchyma and
vessels where various inflammatory cells are increased and
release a variety of mediators.1 The injury and repair cycle
caused by the chronic inflammation can result in structural
airway remodeling with increased fibrosis2,3 that narrows and
fixes the airway lumen. It is generally accepted that cigarette
smoking is the most important risk factor for COPD. However,
only 10–15% of smokers develop the severe impairment of
pulmonary function associated with COPD.4 The Global
Initiative on Chronic Obstructive Lung Disease (GOLD) reported
that the repeated exposure to pollutants, chronic or latent
viral infection and genetic factors enhance the susceptibility
to COPD in smokers.5 The familial clustering of patients with
early onset COPD6 and the differences in the prevalence of
COPD among different racial groups strongly suggest that
genetic factors may contribute the susceptibility to COPD.
Transforming growth factor-b1 (TGF-b1) is multifunc-
tional growth factor that has numerous biological effects
such as induction of fibroblast proliferation and extracel-
lular matrix production, decreased collagen degradation,7
chemotaxis of macrophages and mast cells and inhibition of
epithelial cell growth.8 TGF-b1 is also a switching factor for
IgA and induces production of IgA with or without LPS and IL4
stimulation.9 Previous reports showed that TGF-b1 expres-
sion was increased in the airways of COPD patients.1,8,10 On
the other hand, lack of activation of latent TGF-b1-induced
emphysema-like alveolar destruction in an animal model.11
Wu et al.12 reported an association between COPD and the
Leu–Leu genotype at codon 10. The Leu allele is associated
with lower production of TGF-b1 genotype and therefore the
authors concluded that TGF-b1 could have a protective role
in COPD. Importantly, this result was replicated in a larger
COPD case–control study by Celedo´n et al.13
The TGF-b1 gene contains several variants14,15 and we
focused on three single nucleotide polymorphisms that had
been associated with gene expression and/or susceptibility to
disease in previous studies: a C-T transition at nucleotide
509 which is located in the 50 flanking region of the gene, a
T-C transition at nucleotide +869 which leads to the Leu10Pro
amino acid substitution and a G-C transversion at nucleotide
+915 which leads to the Arg25Pro amino acid substitution.
We investigated whether these three polymorphisms of the
TGF-b1 gene were associated with an accelerated rate of
decline of forced expiratory volume in 1 s (FEV1) in the Lung
Health Study (LHS). We also investigated the association of
these polymorphisms with airway hyperresponsiveness. The
LHS, sponsored by the National Heart, Lung and Blood Institute,
was a clinical trial of smoking intervention and bronchodilator
usage on the progression of COPD.16 This dataset provides an
excellent opportunity to test the relationship between TGF-b1
gene polymorphisms and the rate of decline of FEV1.
Methods
Study participants
We performed a nested case control study of 283 Caucasian
individuals who had the fastest decline of FEV1 and 307Caucasian individuals who had the slowest decline from 3216
study participants who continued to smoke during 5 years of
follow-up in the LHS. Spirometry was performed annually
over a period of 5 years as previously described.16 Lung
function was assessed as pre-bronchodilator FEV1% pre-
dicted, i.e. FEV1 adjusted for age, height, and sex.
17 The
rate of decline was expressed as the average decline in
FEV1% predicted per year over the 5 years of follow-up.
Arbitrary cut-off points of FEV1% predicted decreaseX3.0%/
year and increaseX0.4%/year were used for rapid decliners
and non-decliners, respectively. Among 590 participants in
this study methacholine responsiveness was measured in 568
(Table 1). The experimental protocol for this study was
approved by the Providence Health Care Research Ethics
Board.
Since airway hyperresponsiveness is one of the risk
factors of COPD5 we used methacholine responsiveness as
an additional outcome variable in this study. Measure
ment of the responsiveness of the airways to methacholine
was expressed as a dose-response slope, i.e. the difference
between the lowest post-challenge in FEV1 and baseline
FEV1 divided by the cumulative dose of metha
choline administered (in units of % decline in FEV1/mmol
of methacholine).18 Due to the selection of the study
participants the distribution of methacholine respon
siveness was bimodal. Therefore, we used a dicho
tomized variable for this analysis, i.e. low responsiveness
(O’Connor slope X60) and high responsiveness (O’Connor
slope p60).Genotyping
As shown in Fig. 1, detection of the polymorphisms of
the TGF-b1 gene was performed using polymerase
chain reaction (PCR)—restriction fragment length poly-
morphism methods. Briefly, to determine the genotype
of the C-509T polymorphism, PCR was done using the
forward primer (50-GTC CCT CTG GGC CCA GTT TC-30) and
the reverse primer (50-GAG GGG GCA ACA GGA CAC CTTA-30)
that has a mismatch (the underlined base) to introduce
an Afl II restriction site into the PCR product when there
is a C to T base exchange at 509. After amplification, the
PCR products were digested overnight at 37 1C with five
units of Afl II restriction enzyme. The C allele yielded a
fragment of 178 bp, while the T allele yielded fragments
of 159 and 19 bp. To determine the genotype of the
T+869C and G+915C polymorphisms, PCR was done using
the forward primer (50-TTC CCT CGA GGC CCT CCT A-30) and
the reverse primer (50-GCC GCA GCT TGG ACA GGA TC-30),
which were designed according to the published se-
quences.19 After amplification, for T+869C genotyping the
PCR products were digested overnight at 37 1C with five
units of MspA1 I restriction enzyme. The T allele
yielded fragments of 161, 67, 40 and 26 bp, while the C
allele yielded fragments of 149, 67, 40, 26 and 12 bp. For
G+915C genotyping, the PCR products were digested over-
night at 37 1C with five units of Bgl I restriction enzyme. The
G allele yielded fragments of 131, 103 and 60 bp, while the C
allele yielded fragments of 131 and 163 bp. Genotypes were
scored without knowledge of the phenotypes by two
observers.
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Table 1 The characteristics of the study participants.
Fast decliners (n ¼ 283) Non-decliners (n ¼ 307) P-value
Male/female 165/118 204/103 0.04
Age (years) 49.670.4 47.670.4 0.0004
Smoking history (pack year) 43.271.2 38.371.0 0.0018
DFEV1 (ml/year)
y 153.872.6 14.871.5 o0.0001
DFEV1 (% predicted/year)
z 4.1570.06 1.0870.04 o0.0001
Baseline FEV1 (l)
y 2.4770.03 2.7070.03 o0.0001
Baseline FEV1 (% predicted)
J 72.570.5 75.670.5 o0.0001
Bronchodilator response (%)z 3.2870.33 5.8670.31 o0.0001
Methacholine response (O’ Connor slope)# 23.472.0 7.870.9 o0.0001
Methacholine high/low responder 35/237 6/290 o0.0001
All variables are baseline characteristics with the exception of DFEV1/year.
Values are means7SE.
Number of packs of cigarettes smoked per day number of years of smoking.
yChange in pre-bronchodilator lung function over a 5-year period measured as ml (mean number of observations per
participant ¼ 4.7, range 1–5).
zChange in lung function over a 5-year period measured as pre-bronchodilator FEV1 % predicted. Percent predicted values are
adjusted for height, age and sex.
yLung function at the start of the study measured as ml.
JLung function at the start of the study measured as % predicted.
zPercent change in FEV1 from baseline in response to a bronchodilator.
#Measurement of the responsiveness of the airways to methacholine expressed as percent decline in FEV1 per final cumulative dose
of methacholine administered (data only available for 568 participants).
O’Connor slope p60/O’Connor slope X60.
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Figure 1 The three polymorphisms in the transforming growth factor (TGF)-b1 gene and the electrophoretic images after digestion
with the restriction enzymes. Panel (A) The three polymorphisms in the TGF-b1 gene. Panel (B) The C-509T polymorphism was
identified by an artificial Afl II restriction site introduced by a mismatch in one of the PCR primers. The C allele yielded a fragment of
178 bp, while the T allele yielded fragments of 159 and 19 bp. Panel C: The T+869C polymorphism was identified with MspA1 I
digestion. The T allele yielded fragments of 161, 67, 40 and 26 bp, while the C allele yielded fragments of 149, 67, 40, 26 and 12 bp.
Panel D: The G+915C polymorphism was identified with Bgl I digestion. The G allele yielded fragments of 131, 103 and 60 bp, while
the C allele yielded fragments of 131 and 163 bp.
E. Ogawa et al.940Data analysis
Demographic characteristics in the two study groups were
compared by w2 analysis for categorical variables and t-tests
for continuous variables. The frequencies of the alleles andgenotypes between rapid and non-decliner groups were
compared by w2 analyses for 3 2 contingency tables, unless
otherwise stated. Significant associations were also ana-
lyzed by logistic regression to adjust for potential confound-
ing factors. P-values less than 0.05 were considered
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program (SAS Institute Inc., Cary, NC, USA). Haplotype
frequencies, linkage disequilibrium, and Hardy–Weinberg
equilibrium were calculated using the Arlequin software
package.20 Linkage disequilibrium (the association between
alleles of different polymorphisms in a population of
unrelated individuals) was assessed by calculating the D0
statistic. This is the coefficient of linkage disequilibrium D
expressed as a proportion of its maximum value (Dmax) given
the observed allele frequencies.Results
The characteristics of the 590 smokers are given in Table 1.
In the fast decline group, the range of values was from 3.0
to 8.8 in terms of change in % predicted FEV1 per year. The
corresponding range of absolute values was 78 to 366ml
per year. All individuals were Caucasian and there were
significant differences in several potential confounding
factors such as age, sex and cigarette-smoking history
(pack-years) between fast/non-lung function declineTable 2 The frequencies of genotypes at the three
polymorphic sites within each phenotype group.
Fast
decliners
Non-
decliners
P-
value
Genotype (509)
CC 134 (49%) 163 (55%) 0.40
CT 110 (40%) 106 (36%)
TT 28 (10%) 28 (9%)
Total 272 297
Genotype (T+869C)
TT 101 (39%) 115 (39%) 0.74
TC 122 (47%) 141 (48%)
CC 38 (15%) 36 (12%)
Total 261 292
Genotype (G+915C)
GG 249 (88%) 265 (86%) 0.35
GC 34 (12%) 39 (13%)
CC 0 3 (1%)
Total 283 307
Genotyping assays were not successful for 21 samples for the
509 polymorphism and 27 samples for the T+869C poly-
morphism.
Fisher’s exact test.
Table 3 The haplotype frequencies estimated within the study
C–C–C C–C–G C–T
Fast decliners 31 (6%) 19 (4%) 306
Non-decliners 40 (7%) 21 (4%) 352
Total 71 (7%) 40 (4%) 658
Loci are presented in the order 509, T+869C, G+915C. There was no
fast and non-decliner groups (P ¼ 0:76). The total number of hapl
complete genotypic data across the three polymorphisms were inclugroups. Therefore, the associations of alleles, genotypes
and haplotypes with lung function were analyzed by logistic
regression to adjust for these factors. Three polymorphisms
in the TGF-b1 were determined in this association study. The
distributions of C-509T, T+869C and G+915C genotypes in the
rapid and non-decliner groups are detailed in Table 2. The
overall observed distribution of homozygotes and hetero-
zygotes for each polymorphism conformed to expectations
based on Hardy–Weinberg analysis. There was no association
with rate of decline of lung function with any genotypes
(Table 2) and the differences were not significant after
adjustment for the significantly different baseline values
(age, pack-years, gender and initial level of lung function).
Furthermore, haplotype analysis of the three TGF-b1
polymorphisms did not reveal an association with rate of
decline of lung function (Table 3). There was significant
linkage disequilibrium between all three loci (Table 4).
In a post-hoc analysis, the distribution of +869 genotypes
was significantly different in high responders to methacho-
line compared with the low responders (Table 5). Specifi-
cally, the frequency of the CC genotype was more than
doubled in the high responders. This increased CC frequency
remained significant after adjustment for age, gender,
smoking history (pack-year), baseline lung function and rate
of decline of lung function (odds ratio ¼ 3.0, 95%
CI ¼ 1.2–7.0, P ¼ 0:01) when compared with the CT and TT
individuals combined.Discussion
In the present study, we investigated whether polymorph-
isms of the TGF-b1 gene were associated with the rate of
decline of lung function in smokers. None of the genotypes
or haplotypes had a statistically significant effect on the
rate of decline of lung function. However, one of these
polymorphisms, which is located at position +869 of the TGF-patients.
–G T–C–G T–T–G Total
(60%) 143 (28%) 7 (1%) 506
(62%) 144 (25%) 11 (2%) 568
(61%) 287 (27%) 18 (2%) 1074
significant difference in the haplotype distribution between the
otypes does not add up to 1180 because only individuals with
ded in the analysis.
Table 4 Linkage disequilibrium values between the
TGF-b1 polymorphisms.
509 T+869C G+915C
509 0.90 1.00
T+869C 0.54 1.00
G+915C 0.03 0.12
Numbers above the diagonal are D0 (D/Dmax) and below the
line are r2 values. Linkage disequilibrium between all three
loci was highly significant (Po0:0001).
ARTICLE IN PRESS
Table 5 The frequencies of genotypes at the T+869C
polymorphic site within methacholine responsiveness
groups.
Genotype (T+869C) High Low P-value
Homozygous TT 14 (37%) 195 (39%) 0.04
Heterozygous TC 14 (37%) 239 (48%)
Homozygous CC 10 (26%) 61 (12%)
Total 38 495
E. Ogawa et al.942b1 gene, was associated with airway hyperresponsiveness to
methacholine.
The T allele at 509 creates a putative YY1 transcription
factor binding site21 that has been associated with COPD,13
asthma,22 asthma severity,23 higher serum TGF-b1,24 higher
total serum IgE21 and increased YY1 binding and reporter
gene activity.22 Homozygosity (Pro/Pro) at codon 1025,26 and
homozygosity (Arg/Arg) at codon 2527 are high producer
genotypes of TGF-b1. The Leu10 isoform was associated with
accelerated decline in lung function of patients with cystic
fibrosis.28 Wu et al.12 reported that the Leu/Leu genotype at
codon 10 was significantly increased in COPD patients
compared with controls. These data are consistent with
integrin avb6 knockout mice which developed emphysema
that could be abrogated by transgenic expression of active
TGF-b1 (11). Celedo´n and colleagues13 demonstrated link-
age between the chromosomal region containing the TGF-b1
gene and lung function in a cohort of early onset COPD
families. The same authors showed that the 509C and
Leu10 alleles were significantly increased in COPD patients
versus controls.13 More recently, Su et al.29 have shown that
the 509C allele is increased in COPD patients from the
Chinese population.
Therefore, the results of these genetic studies are
consistent and suggest that decreased level of TGF-b1 is a
risk factor for the development of COPD. However, TGF-b1
has a wide array of functions and it is not clear which are
relevant if this observation is true. It is possible that TGF-b1
protects against decline in lung function or it may be
involved in lung development or response to infection. In
contrast, previous studies showed that TGF-b1 expression
was increased in the airways of COPD patients.1,8,10
There are several possible reasons that we did not
replicate the previous associations of TGF-b1 polymorphisms
and COPD. One reason is the difference in the phenotype of
the study subjects. Wu et al.,12 Celedo´n et al.13 and Su
et al.29 compared subjects who had already developed COPD
with smokers who had normal lung function, whereas in this
study we focused on the acceleration of decline in FEV1. The
underlying pathology of COPD is mixture of airway and
parenchyma lesions. TGF-b1 could have a protective role
against the destruction of alveoli leading to emphysema but
not against airway remodeling in COPD. It is even possible
that TGF-b1 contributes to airway remodeling by producing
extracellular matrix. Therefore, the impact on lung function
may be less pronounced than for a molecule that protects
against both pathological processes. The effect of the TGF-
b1 polymorphisms may only become evident after a long
period of time and the individuals in this study wereconsiderably younger than those in the previous stu-
dies.12,13,29
Another reason for lack of replication is the number of the
subjects in the study. Our study included more subjects than
two of the previous studies,12,29 but fewer than the study of
Celedo´n et al.13 Therefore, we cannot rule out the
possibility that the lack of association in this study was a
false negative result.
The range of FEV1 baseline levels in the fast decliners was
54.9–90.6% of predicted, and therefore a few of these
individuals would not have been classified as COPD patients
at the start of the study. However, the phenotype that we
studied was rate of decline of lung function rather than
COPD per se. The rationale for this was that rate of decline
of lung function is a more precise phenotype than a single
cross-sectional measurement of lung function. Lung function
normally increases to a maximal value at adulthood and
begins to decline 10–15 years later. COPD can develop
because of a reduced maximal lung function, an earlier age
of onset of decline and/or an accelerated rate of decline.
Different genetic variants may influence these processes and
therefore the study of rate of decline may allow a more
genetically homogeneous phenotype to be studied.
Previous studies have shown that increased airway
hyperresponsiveness to histamine was associated with
accelerated decline in FEV1
30 and airway hyperresponsive-
ness was identified as one of the risk factors that contribute
to the development of COPD.5 In this study, a post-hoc
analysis found a significant association between +869
genotypes and airway hyperresponsiveness to methacholine.
However, there was no significant correlation between TGF-
b1 polymorphisms and decline of FEV1 and this may reflect
the small numbers of participants in the high responder
group.
In summary, there was no association between TGF-b1
polymorphisms and the rate of decline of FEV1, but the
genotype distribution of the +869 amino acid substitution
was significantly different between high and low responders
to methacholine. These data suggest that the +869
polymorphism in the TGF-b1 gene contributes to airway
hyperresponsiveness.Acknowledgments
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